The NexEos Bio management team and NexEos’ collaborators at The University of Utah include highly-seasoned biopharmaceutical professionals with several decades of experience in both the field of eosinophil research and pharmaceutical development and commercialization. Scientific Founder and Chief Scientific Officer Gerald Gleich, MD, was the clinical investigator who first identified and characterized the major proteins of the distinctive eosinophil granules and described several novel clinical syndromes, including Episodic Angioedema with Eosinophilia (EAE), which is also known as Gleich Syndrome. Other collaborators on the team actively manage patients with EoE in their clinical practices. A number of team members have been leaders in the development of therapeutics for the treatment of a host of eosinophil-mediated disorders including EoE, eosinophil-mediated asthma and the hypereosinophilic syndrome (HES). Collectively, they have brought several programs successfully through U.S. Food & Drug Administration (FDA) approval and to the market to further science and improve patients’ lives.

"Many NexEos executive team members have been leaders in the development of therapeutics for the treatment of a host of eosinophil-mediated disorders. Collectively, we have brought several programs successfully through FDA approval and to the market to further science and improve patients’ lives. We look forward to doing the same on the diagnostics side here at NexEos."

Theresa Mansi, Chief Executive Officer


Theresa Mansi

Chief Executive Officer

Theresa Mansi has served as Chief Executive Officer and member of the Board of Directors at NexEos since its inception in 2019. Over 30 years in the pharmaceutical and biotech industry, Theresa’s accomplishments have spanned Global Business Development, Ventures, Product Development, Strategic Marketing and Market Research. Formerly, Theresa was Vice President of the Global Business Insights division of DRG, the premier provider of healthcare data and insights. Prior to DRG, Theresa worked for GSK for more than 20 years in roles of increasing responsibility. As Senior Director Worldwide Business Development, she negotiated complex deals, closing several U.S., Japanese and European licensing and M&A deals. Theresa also headed GSK’s Ventures group where she led a team of entrepreneurs who created start-up companies with funding from a variety of sources. Early on, Theresa established GSK’s Global Marketing Research department while living in London. Theresa is a Certified Licensing Professional with an MBA in International Marketing from Saint Joseph’s University. She has completed Executive Education Programs at Darden University and the Wharton School. 

Gerald Gleich, MD

Co-Founder & Chief Scientific Officer

Dr. Jerry Gleich has had a life-long passion and professional commitment to understanding the eosinophil in human biology. This interest began during his residency training and was stimulated by caring for patients with bronchial asthma hospitalized at Mayo Clinic. The focus of his work on the eosinophil has been on the distinctive granules. He and his colleagues have isolated, characterized, identified the cDNAs and the genes, and established assays for measurement and localization of all of the granule proteins. In turn, these efforts led to the recognition that eosinophil degranulation with release of cytotoxic and cytostimulatory cationic molecules into tissues is characteristic of eosinophil-related diseases. These efforts also led to the recognition of several novel syndromes, including episodic angioedema associated with eosinophilia (Gleich syndrome) and the eosinophil-myalgia syndrome. 

Jerry received his medical degree from the University of Michigan. He obtained residency training in Internal Medicine at the Philadelphia General Hospital and the Jackson Memorial Hospital at the University of Miami and was a flight surgeon in the United States Air Force. He received postdoctoral training at the University of Rochester and then established a research laboratory for allergic diseases at the Mayo Clinic. While at Mayo, he was Professor of Medicine and Immunology, Chairman of the Department of Immunology. Jerry is an emeritus Professor of Pediatrics at Primary Children’s Medical Center in Salt Lake City, Utah, and has had an allergy medicine practice for 11 years at the Veterans Administration Medical Center in Salt Lake City, Utah. Presently, he is Professor of Dermatology and Medicine at The University of Utah as well as a founder and Chief Scientific Officer of NexEos Bio.


Jerry has served as Chairman of the World Health Organization Subcommittee on Standardization of Allergens, on the Allergy and Clinical Immunology Research Committee of the National Institute of Allergy and Infectious Diseases, on the editorial board of Journal of Allergy And Clinical Immunology, on the editorial board of the Journal of Immunology, as Member and Chairman of the Board of Scientific Counselors, National Institute of Allergy and Infectious Diseases (NIAID), and as Member and Chair of the Data and Safety Monitoring Board of NIAID. Jerry is a charter member and past president of the International Eosinophil Society (IES). He is a medical advisor to the American Partnership for Eosinophilic Disorders (APFED) Board of Directors. 

Lyn Caltabiano, PhD

Project Management

An established leader in global pharmaceutical research and development, Lyn has more than 35 years of experience in all phases of drug development and discovery research including project management, early and late clinical operations, business development and alliance management. Beginning her career as a bench scientist at Smith, Kline & French in 1981, Lyn transitioned to drug development in 1991, assuming positions of increasing responsibility in project management. She was a member of the GlaxoSmithKline (GSK) merger team, built the GSK R&D Alliance Management organization, headed project operations in Oncology R&D and led the development of several new therapeutics. Transitioning to Merck Research Laboratories in 2014 as Senior Vice President, Global Project and Alliance Management, Lyn rebuilt the R&D Project and Alliance Management organizations and led the development of a critical portfolio management and executive decision-making processes. With a comprehensive background in drug development and project management, Lyn’s drug development accountabilities have included the definition, development and delivery of vision, strategy and operational plans, identification and management of resource requirements, and alliance management of external stakeholders and collaborators including in-licensing partners, government funding agencies and strategic CRO collaborators. Lyn earned her PhD in Pathology and Laboratory Medicine from the University of Pennsylvania.

Kelly Copeland

Commercial Strategy

Kelly has more than 20 years of experience working in the healthcare industry, primarily in the development of pharmaceutical products. She spent six years with GlaxoSmithKline providing commercial strategy and product development support to programs from pre-clinical stages of development through to global registration. Over the past 13 years, Kelly has been working with small teams of seasoned drug developers to identify promising assets, build companies around them, raise funding, design and implement strategic development plans and drive the companies to successful outcomes for both the products as well as investors. She has been a founding team member of seven biotech start-ups – three of which have led to product approvals and four to a successful exit for investors. In addition, Kelly has spent a number of years working in the space of eosinophil-mediated disease – working as a key team member on two products that have been approved in the US and Europe for the treatment of eosinophil-mediated conditions. In addition to her role with NexEos, Kelly is a partner with NeXeption. 


Previously, Kelly served as the Vice President of Commercial Strategy for Onspira Therapeutics, Inc. (acquired by Altavant Sciences), Vice President of Product Strategy and Marketing for Ceptaris Therapeutics (acquired by Actelion) and Vice President of Product Strategy and Business Development for Ception Therapeutics (acquired by Cephalon), Aclaris Therapeutics (IPO 2015), Ralexar Therapeutics and Velicept Therapeutics. She earned her MS in Health Services Administration and a BS from the University of Michigan. Additionally, she completed a post-graduate fellowship with Henry Ford Health System. 

Shivani Chandhok DPM, MS

Clinical Development, Operations

Shivani brings six years of clinical experience in addition to three years of pre-clinical research experience to NexEos. Born and raised in Nairobi, Kenya, Shivani came to North America in 1991, completed her early education, and subsequently obtained a BS at Simon Fraser University in Canada, her MS degree at Drexel University College of Medicine and her DPM from Temple University School of Podiatric Medicine. She completed a four-year surgical residency at University of Pennsylvania Presbyterian Medical Center.


Shivani participated in non-invasive cardiovascular imaging research at the University of Pittsburgh both as part of the McGowan Institute of Regenerative Medicine as well as at the Heart and Vascular Institute at UPMC. She has numerous scientific publications in the pre-clinical research space with a specific focus on studies utilizing fluorescent tagged microbubbles targeted to endothelial inflammatory markers VEG-F and TNFα. Her diverse clinical and research background makes Shivani sensitive to both the immediate and long-terms goals of patients affected by chronic, eosinophil-related diseases and conditions.

NEXEOS BIO White Logo 2020MAR16 F CMYK-0

NexEos Bio

PO Box 1209

Pottstown, PA 19464


© 2020 Copyright NexEos Bio. All rights reserved.